TOP 10 Oncologia de Precisão

OSWALDO CRUZ
11/19/21, 11:00 AM
America/Sao_Paulo GMT -3

Description

08:00 - 08:20

ARTIGO 1 - KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.

Hong, D. N Engl J Med 2020; 383:1207

08:20 - 08:40

ARTIGO 2 - Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial.

Siena, S. Lancet Oncol 2021; 22(6):779

08:40 - 09:00

ARTIGO 3 - Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study.

Oark, K. J Clin Oncol 2021; JCO2100662

09:00 - 09:20

ARTIGO 4 - Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer.

Wu, Y. N Engl J Med 2020; 383:1711

09:20 - 09:40

ARTIGO 5 - Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study.

Javle, M. Lancet Gastroenterol Hepatol 2021; 6(10):803

09:40 - 10:00

ARTIGO 6 - Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis.

Choueiri, T. Nat Med 2021; 27(5):802

10:00 - 10:40

INTERVALO

10:40 - 11:00

ARTIGO 7 - Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration.

Abida, W. J Clin Oncol 2020; 38(32):3763

11:00 - 11:20

ARTIGO 8 - Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial.

Blay, JY. Lancet Oncol 2020; 21(7):923

11:20 - 11:40

ARTIGO 9 - Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.

Sartor, O. N Engl J Med 2021 Jun 23. Online ahead of print

11:40 - 12:00

ARTIGO 10 - Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer.

Parikh, A. Clin Cancer Res 2021 Apr 29. Online ahead of print

Previous registration necessary?

NO

YES
Simultaneous translation ?

NO

YES
Will it be recorded?
NO
YES

Marcos André Costa

ARTIGO 1 - KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors, ARTIGO 2 - Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial, ARTIGO 3 - Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study, ARTIGO 4 - Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer, ARTIGO 5 - Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study, ARTIGO 6 - Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis, ARTIGO 7 - Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration, ARTIGO 8 - Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial, ARTIGO 9 - Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer, ARTIGO 10 - Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer

Inglês

 

Speakers

FERNANDO SANTINI, RODRIGO GUEDES, SAMIRA MASCARENHAS, GUSTAVO STOCK, RICARDO CAPONERO, FABIO SCHUTZ, ANDRE MURAD, RENATA D’ALPINO, ARIEL KANN, ALESSANDRO LEAL